CSIMarket
 


Penumbra Inc  (NYSE: PEN)
Other Ticker:  
 
 

PEN's Revenue Growth by Quarter and Year

Penumbra Inc's Revenue results by quarter and year

 



PEN Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December - 315.52 284.68 221.22
3rd Quarter September - 301.04 270.95 213.68
2nd Quarter June - 299.40 261.50 208.34
1st Quarter March 324.14 278.66 241.40 203.90
FY   324.14 1,194.62 1,058.53 847.14

PENs Annual Revenue
Penumbra Inc's Revenue in the fiscal year 2024 $ 1,194.62 millions
Penumbra Inc's Revenue in the fiscal year 2023 $ 1,058.52 millions
Penumbra Inc's Revenue in the fiscal year 2022 $ 847.13 millions
Penumbra Inc's Revenue in the fiscal year 2021 $ 747.59 millions
Penumbra Inc's Revenue in the fiscal year 2020 $ 560.41 millions




PEN Revenue first quarter 2025 Y/Y Growth Comment
Penumbra Inc reported Revenue increase of 16.32% year on year in the first quarter 2025, to $ 324.14 millions, this is lower than Penumbra Inc's recent average Revenue improvement of 28.04%.

Looking into first quarter 2025 results within Medical Equipment & Supplies industry 74 other companies have achieved higher Revenue growth. While Penumbra Inc' s Revenue growth of 16.32% ranks overall at the positon no. 1384 in the first quarter 2025.




PEN Revenue ( Y/Y Growth %) 2025
2024 2023 2022
4th Quarter December - 10.83 % 28.69 % 8.44 %
3rd Quarter September - 11.11 % 26.8 % 12.39 %
2nd Quarter June - 14.49 % 25.52 % 13.07 %
1st Quarter March 16.32 % 15.43 % 18.39 % 20.51 %
FY   - 12.86 % 24.95 % 13.32 %

Financial Statements
Penumbra Inc's first quarter 2025 Revenue $ 324.14 millions PEN's Income Statement
Penumbra Inc's first quarter 2024 Revenue $ 278.66 millions Quarterly PEN's Income Statement


PEN Revenue (Quarter on Quarter Growth %)

2025
2024 2023 2022
4th Quarter December - 4.81 % 5.07 % 3.53 %
3rd Quarter September - 0.55 % 3.61 % 2.56 %
2nd Quarter June - 7.44 % 8.33 % 2.18 %
1st Quarter March 2.73 % -2.11 % 9.12 % -0.05 %
FY (Year on Year)   - 12.86 % 24.95 % 13.32 %




Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #75
Healthcare Sector #248
Overall #1384

Revenue Y/Y Growth Statistics
High Average Low
139.05 % 28.04 % 2.38 %
(Jun 30 2017)  
Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #75
Healthcare Sector #248
Overall #1384
Revenue Y/Y Growth Statistics
High Average Low
139.05 % 28.04 % 2.38 %
(Jun 30 2017)  

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Penumbra Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
43.73 % 5.27 % -23.46 %
(Sep 30 2020)  


PEN's I. Quarter Q/Q Revenue Comment
Penumbra Inc achieved in the I. Quarter 2025 below company average Revenue growth of 2.73% quarter on quarter, to $ 324.14 millions.

I. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -2.11% in the I. Quarter a year ago.

Within Medical Equipment & Supplies industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Penumbra Inc's Revenue growth quarter on quarter, overall rank is 1164.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #44
Healthcare Sector #178
Overall #1164
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #44
Healthcare Sector #178
Overall #1164
Revenue Q/Q Growth Statistics
High Average Low
43.73 % 5.27 % -23.46 %
(Sep 30 2020)  


PEN's I. Quarter Q/Q Revenue Comment
Penumbra Inc achieved in the I. Quarter 2025 below company average Revenue growth of 2.73% quarter on quarter, to $ 324.14 millions.

I. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -2.11% in the I. Quarter a year ago.

Within Medical Equipment & Supplies industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Penumbra Inc's Revenue growth quarter on quarter, overall rank is 1164.


Penumbra Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)
12 Months Ending
(Dec 31 2024)
12 Months Ending
(Sep 30 2024)
12 Months Ending
(Jun 30 2024)
12 Months Ending
(Mar 31 2024)
Cumulative Revenue 12 Months Ending $ 1,240.10 $ 1,194.62 $ 1,163.78 $ 1,133.68 $ 1,095.78
Y / Y Revenue Growth (TTM) 13.17 % 12.86 % 16.96 % 20.89 % 23.87 %
Year on Year Revenue Growth Overall Ranking # 367 # 103 # 112 # 106 # 519
Seqeuential Revenue Change (TTM) 3.81 % 2.65 % 2.65 % 3.46 % 3.52 %
Seq. Revenue Growth (TTM) Overall Ranking # 1384 # 450 # 376 # 274 # 955


Cumulative Revenue growth Comment
Although Penumbra Inc's Annual Revenue growth year on year were below company's average 28.04% , Revenue announced in the Mar 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 13.17% year on year, from 12.86% in Dec 31 2024.

In the Healthcare sector 105 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 103 to 367.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 75
Healthcare Sector # 106
Overall # 367

Revenue TTM Y/Y Growth Statistics
High Average Low
139.05 %
28.04 %
2.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 75
Sector # 248
S&P 500 # 1384
Cumulative Revenue growth Comment
Although Penumbra Inc's Annual Revenue growth year on year were below company's average 28.04% , Revenue announced in the Mar 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 13.17% year on year, from 12.86% in Dec 31 2024.

In the Healthcare sector 105 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 103 to 367.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 75
Healthcare Sector # 106
Overall # 367

Revenue TTM Y/Y Growth Statistics
High Average Low
139.05 %
28.04 %
2.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 75
Sector # 248
S&P 500 # 1384




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PEN's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for PEN's Competitors
Revenue Growth for Penumbra Inc's Suppliers
Revenue Growth for PEN's Customers

You may also want to know
PEN's Annual Growth Rates PEN's Profitability Ratios PEN's Asset Turnover Ratio PEN's Dividend Growth
PEN's Roe PEN's Valuation Ratios PEN's Financial Strength Ratios PEN's Dividend Payout Ratio
PEN's Roa PEN's Inventory Turnover Ratio PEN's Growth Rates PEN's Dividend Comparisons



Companies with similar Revenue growth for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2025
Rapid Micro Biosystems Inc 28.41%$ 28.408 millions
Immucell Corp28.14%$ 28.145 millions
Sanara Medtech Inc 28.07%$ 28.065 millions
Ultragenyx Pharmaceutical Inc 27.99%$ 27.987 millions
Adc Therapeutics Sa27.59%$ 27.585 millions
Ginkgo Bioworks Holdings Inc 27.34%$ 27.340 millions
Rhythm Pharmaceuticals inc 25.94%$ 25.944 millions
Precigen Inc 25.92%$ 25.915 millions
Femasys Inc25.86%$ 25.863 millions
National Healthcare Corp25.75%$ 25.749 millions
Cardiff Lexington Corporation25.56%$ 25.556 millions
Adaptive Biotechnologies Corporation25.24%$ 25.243 millions
Glaukos Corp24.58%$ 24.582 millions
Aurinia Pharmaceuticals Inc 24.18%$ 24.177 millions
Pulmonx Corporation23.59%$ 23.587 millions
Si bone inc 23.32%$ 23.320 millions
Twist Bioscience Corporation23.23%$ 23.228 millions
Electrocore Inc 23.20%$ 23.204 millions
Inspire Medical Systems inc 22.88%$ 22.882 millions
Cytomx Therapeutics Inc 22.80%$ 22.801 millions
Collegium Pharmaceutical inc 22.75%$ 22.753 millions
Tandem Diabetes Care Inc 22.30%$ 22.296 millions
Zai Lab Limited22.19%$ 22.190 millions
Alphatec Holdings Inc 22.15%$ 22.150 millions
Pro dex Inc 21.84%$ 21.836 millions
Lifevantage Corp21.33%$ 21.330 millions
Cvrx inc 21.24%$ 21.241 millions
Biodesix Inc 21.19%$ 21.190 millions
Boston Scientific Corporation20.90%$ 20.897 millions
Guardant Health Inc 20.76%$ 20.761 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com